Solstein Capital LLC Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Solstein Capital LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 26.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,277 shares of the company’s stock after selling 5,560 shares during the quarter. Solstein Capital LLC’s holdings in Novo Nordisk A/S were worth $1,061,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after buying an additional 23,223 shares in the last quarter. Bryn Mawr Capital Management LLC raised its stake in Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after buying an additional 30,420 shares in the last quarter. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after buying an additional 286,912 shares in the last quarter. CIBC Asset Management Inc grew its holdings in Novo Nordisk A/S by 5.7% in the fourth quarter. CIBC Asset Management Inc now owns 73,547 shares of the company’s stock worth $6,254,000 after purchasing an additional 3,989 shares during the period. Finally, Hourglass Capital LLC increased its stake in shares of Novo Nordisk A/S by 21.3% during the fourth quarter. Hourglass Capital LLC now owns 18,950 shares of the company’s stock valued at $1,630,000 after purchasing an additional 3,330 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NVO shares. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating for the company. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $79.90 on Monday. The company has a market capitalization of $358.57 billion, a P/E ratio of 24.29, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average of $67.30 and a 200 day moving average of $79.45. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.